I joined the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) in 2020. BADBIR is a pharmacovigilence register established in 2007 to evaluate the long-term safety and effectiveness of systemic therapy for psoriasis in real-world patient populations across the UK and Republic of Ireland. My primary responsibilities include conducting advanced statistical analyses and contributing to peer-reviewed publications. My research interests focus particularly on the safety profile of systemic therapies for patients with moderate-to-severe psoriasis.